Stereoselective pharmacokinetics and pharmacodynamics of anti-asthma agents

Annals of Pharmacotherapy

Volumn 36, Issue 4, 2002, Pages 693-701

  Vakily, Majid ^a   Mehvar, Reza ^a   Brocks, Dion ^a   Nazario, Mitchell ^a   Parent, Marc ^a  

^a TAP Pharmaceuticals   (United States)

Author keywords

Asthma drugs; Chiral 2 agonists; Enantiomer; Stereoselective pharmacodynamics; Stereoselective pharmacokinetics

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLENBUTEROL; FORMOTEROL; IPRATROPIUM BROMIDE; ISOPRENALINE; LIPOXYGENASE INHIBITOR; ORCIPRENALINE; SALBUTAMOL; TERBUTALINE; TRETOQUINOL; ZILEUTON;

AREA UNDER THE CURVE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; ENANTIOMER; HUMAN; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY; TACHYPHYLAXIS;

EID: 0036206870     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A248     Document Type: Review

References (72)

1. Aerosol therapy for asthma
2. 2-agonist controversy: Observations, explanations, and relationship to asthma epidemiology
3. Asthma management in adults. Strategies to minimize morbidity
4. 2-agonists. Implications for drug therapy
5. Intense pharmacotherapy
6. Basic pharmacotherapy of asthma
7. New directions in asthma drug therapy
8. The drug therapy of asthma: Direction for the 21st century
9. Clinical pharmacokinetics of β-agonists
10. New perspectives for asthma treatment: Anti-leukotriene drugs
11. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotrienel receptor antagonist, in human plasma and bile
12. Enantioselective aspects of drug action and disposition: Therapeutic pitfalls
13. Drug chirality and its clinical significance
14. Stereochemical aspects of pharmacotherapy
15. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle
16. Kinetics of the epimeric glucucorticoid budesonide
17. Anomalous bronchospasm following inhalation of (+) isoprenaline by asthmatic
18. Enantioselective disposition of salbutamol in man following oral and intravenous administration
19. Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man - No evidence of enantioselective lung metabolism
20. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers
21. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects
22. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans
23. Pharmacokinetics of the enantiomers of terbutaline after repeated oral dosing with racemic terbutaline
24. Pharmacokinetic evaluation of terbutaline in man given as separate enantiomers and as the racemate
25. The pharmacokinetics of single oral doses of zileuton 200 to 800 mg, its enantiomers, and its metabolites, in normal healthy volunteers
26. Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods
27. Enantioselective inclusion between terbutaline enantiomers and hydroxypropyl-β-cyclodextrin
28. Stereoselective sulphate conjugation of salbutamol in humans: Comparison of hepatic, intestinal and platelet activity
29. Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography
30. Relative absorption of the two enantiomers of terbutaline after duodenal administration
31. 2-receptor agonists by the human intestine and the recombinant M-form phenolsulfotransferase
32. Transplacental distribution of salbutamol enantiomers at Caesarian section
33. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite
34. Enantioselective disposition of albuterol in humans
35. Stereoselective sulphate conjugation of fenoterol by human phenolsulphotransferases
36. Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells
37. Stereoselective sulfation of albuterol in humans: Biosynthesis of sulfate conjugate by HEP G2 cells
38. Stereoselective glucuronidation of formoterol by human liver microsomes
39. 2-adrenoreceptor stimulant formoterol in urine by gas chromatography mass spectrometry
40. Objective and subjective bronchodilation over 12 hours after inhaled formoterol: Individual responses
41. Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes
42. Enantiomeric activation of zileuton glucuronidation in dog microsomes
43. Serum concentration and cardiovascular effects of salbutamol after oral and rectal administration in healthy volunteers
44. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment
45. Some observations on the adrenoceptor agonist properties of the isomers of salbutamol
46. Absolute configuration of the optical isomers of salbutamol
47. Relative potency of (-)- and (plus-)-salbutamol on guinea pig tracheal tissue
48. Steric aspects of agonism and antagonism at beta-adrenoceptors: Experiments with the enantiomers of terbutaline and pindolol
49. Studies on tetrahydroisoquinolines (THI). VI. Effects of trimetoquinol on tracheal and some other smooth muscles
50. Trimethoquinol-different pharmacological properties of optical isomers
51. Comparison of clenbuterol enantiomers using four psychopharmacological tests sensitive to beta-agonists
52. Steric aspects of agonism and antagonism at beta-adrenoceptors: Experiments with the enantiomers of clenbuterol
53. 2-adrenoceptor agonist, on mucociliary activity
54. Biological significance of the enantiomeric purity of drugs
55. Stereospecificity of the anti-inflammatory action of terbutaline
56. Bradykinin-mediated edema formation is blocked by levorotatory but not dextrorotatory terbutaline
57. 2-adrenergic receptors
58. Preclinical and metabolic profiles of (RR)-eformoterol
59. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol, and racemic salbutamol in patients with bronchial asthma
60. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine
61. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α-, 17α-acetal substituted glucocorticoids
62. Differential responses of asthmatic airways to enantiomers of albuterol
63. 2-adrenoceptor agonists: Is there a cause for concern?
64. Sympathomimetic enantiomers and asthma
65. The asthma-like pharmacology and toxicology of (S)-isomers of β agonists
66. The use of beta-agonists and the risk of death and near death from asthma
67. Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils
68. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma
69. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma
70. Single-isomer beta-agonists
71. New millennium bronchodilators for asthma: Single-isomer beta agonists